What Happened?
New York, -based Synlogic Promoted Brendan St. Amant as General Counsel and Corporate Secretary
Date of management change: June 29, 2022
New York, -based Synlogic Promoted Brendan St. Amant as General Counsel and Corporate Secretary
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic`s approach to Synthetic Biotics with Ginkgo`s Codebase and Foundry services.
Brendan St. Amant is General Counsel and Corporate Secretary at Synlogic. Previously, Brendan held various senior legal leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Balding Stephen, Becker Holly, Martin Laura, O'Connor Nuala, Arnold Kelly, Hittle Sandra, Hatfield Mathew, Chacko Anna, Oakey-Frost RuthAnne, Gutman Michele, Wolf Liza
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.